Published in Br J Pharmacol on February 01, 1971
Evidence of catecholamine mediation in the "aberrant" behaviour induced by lysergic acid diethylamide (LSD) in the rat. Experientia (1968) 1.41
[Effects of D-lysergic acid diethylamide (LSD-25) and 2-bromo-D-lysergic acid diethylamide (BOL-148) on sleeping behavior in rats]. Naunyn Schmiedebergs Arch Pharmakol (1970) 1.31
Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br J Pharmacol (1976) 1.95
[Effects of D-lysergic acid diethylamide (LSD-25) and 2-bromo-D-lysergic acid diethylamide (BOL-148) on sleeping behavior in rats]. Naunyn Schmiedebergs Arch Pharmakol (1970) 1.31
Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther (1986) 1.19
Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.04
SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors. J Pharmacol Exp Ther (2001) 0.97
Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol (1995) 0.92
Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent. Naunyn Schmiedebergs Arch Pharmacol (1974) 0.89
Modifications of sleep structure induced by increasing levels of acoustic perturbation in normal subjects. Electroencephalogr Clin Neurophysiol (1990) 0.88
gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra. J Pharmacol Exp Ther (1982) 0.88
Proceedings: CF 25-397 (9, 10-didehydro-6-methyl-8beta-(2-pyridylthiomethyl) ergoline), a new central dopamine receptor agonist. Br J Pharmacol (1976) 0.88
Antagonist properties of the stereoisomers of ifenprodil at NR1A/NR2A and NR1A/NR2B subtypes of the NMDA receptor expressed in Xenopus oocytes. Eur J Pharmacol (1996) 0.88
The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav (1983) 0.85
Autoradiographic localization of [3H]thiocolchicoside binding sites in the rat brain and spinal cord. Neuropharmacology (2001) 0.85
Some aspects of the polygraphic studies on sleep-wakefulness cycle in rat. Waking Sleeping (1980) 0.83
Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther (1987) 0.82
Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine. Postgrad Med J (1976) 0.81
R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats. Pharmacol Biochem Behav (2001) 0.81
Pharmacokinetics, brain distribution and pharmaco-electrocorticographic profile of zolpidem, a new hypnotic, in the rat. J Pharmacol Exp Ther (1989) 0.80
Antagonist properties of eliprodil and other NMDA receptor antagonists at rat NR1A/NR2A and NR1A/NR2B receptors expressed in Xenopus oocytes. Neurosci Lett (1997) 0.80
Characterization of [3H]thiocolchicoside binding sites in rat spinal cord and cerebral cortex. Eur J Pharmacol (1999) 0.80
The NMDA receptor antagonist eliprodil (SL 82.0715) blocks voltage-operated Ca2+ channels in rat cultured cortical neurons. Eur J Pharmacol (1994) 0.79
Development of stable cell lines expressing different subtypes of GABAA receptors. J Recept Signal Transduct Res (1997) 0.79
Zolpidem functionally discriminates subtypes of native GABAA receptors in acutely dissociated rat striatal and cerebellar neurons. Neuropharmacology (1996) 0.78
Neuropharmacological spectrum of muscimol. Life Sci (1979) 0.78
Inter-group aggression in mice: a new method for testing the effects of centrally active drugs. Psychopharmacologia (1975) 0.78
Preclinical profile of befloxatone, a new reversible MAO-A inhibitor. J Affect Disord (1998) 0.78
Imidazopyridines: towards novel hypnotic and anxiolytic drugs. Farmaco (1991) 0.78
Protracted treatment with diazepam reduces benzodiazepine1 receptor-mediated potentiation of gamma-aminobutyric acid-induced currents in dissociated rat hippocampal neurons. J Pharmacol Exp Ther (1996) 0.77
Proceedings: A quantitative assessment of the effects of clonidine on pre-ganglionic sympathetic nerve activity in the cat. Br J Pharmacol (1974) 0.77
Non-benzodiazepine anxiolytics: potential activity of phenylpiperazines without 3H-diazepam displacing action. Pharmacol Biochem Behav (1985) 0.77
Inhibition of reserpine-induced PGO waves in the cat by ergot derivatives. Experientia (1978) 0.76
Rapid-eye-movement sleep deprivation decreases the density of 3H-dihydroalprenolol and 3H-imipramine binding sites in the rat cerebral cortex. Eur J Pharmacol (1980) 0.76
Hypnotics: clinical value of pharmaco-EEG methods. Neuropsychobiology (1986) 0.76
Polygraphic sleep studies in rats and humans: their use in psychopharmacological research. Arzneimittelforschung (1976) 0.76
Proceedings: Alterations in the sleep-wakefulness cycle in rats after administration of (-)-LSD or BOL-148: a comparison with (+)-LSD. Br J Pharmacol (1972) 0.75
A comparison of apomorphine, bromocriptine and Sandoz CM 29-712 (6-methyl-8a-cyanomethyl-ergoline-l) in four different turning models in the rat [proceedings]. Br J Pharmacol (1978) 0.75
Block of P-type Ca2+ channels by the NMDA receptor antagonist eliprodil in acutely dissociated rat Purkinje cells. Eur J Pharmacol (1995) 0.75
Turning behaviour elicited by apomorphine, (+)-amphetamine and three ergot derivatives in rats treated with a unilateral injection of ethanolamine-O-sulphate in the substantia nigra [proceedings]. Br J Pharmacol (1977) 0.75
Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712. Pharmacology (1978) 0.75
[Clinical evaluation in geriatric psychopharmacology. The point of view of the pharmaceutical industry]. Presse Med (1983) 0.75
[Experimental electropharmacologic studies of cerebral ischemia (author's transl)]. Rev Electroencephalogr Neurophysiol Clin (1982) 0.75
Proceedings: Mechanisms involved in the effect of apomorphine on the extrapyramidal system of the rat. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.75
Neuroprotective effects of eliprodil in a rat hippocampal slice hypoxia model. Ann N Y Acad Sci (1997) 0.75
Neuropharmacological studies on hydergine. Triangle (1975) 0.75
[Pharmacological, pharmacokinetic and toxicological research on mesoridazine (NC 123)]. Boll Chim Farm (1967) 0.75
Drug effects on the EEG of various species of laboratory animals. Neuropsychobiology (1983) 0.75
The prediction of sedative potency of neuroleptics. Mod Probl Pharmacopsychiatry (1970) 0.75
Changes in the rat electrocorticogram following administration of two dihydrogenated ergot derivatives. Gerontology (1978) 0.75
Co-dergocrine. Lancet (1986) 0.75
Neuropharmacology of bromocriptine and dihydroergotoxine (hydergine). Adv Biochem Psychopharmacol (1980) 0.75
Stimulants in senility: a neglected therapeutic option? Pharmacopsychiatry (1984) 0.75
[Effect of vincamine on sleep-wakefulness equilibrium in the cat (author's transl)]. Rev Electroencephalogr Neurophysiol Clin (1978) 0.75
Does cholecystokinin induce physiological satiety and sleep? Brain Res (1989) 0.75
[Alerting effect of vincamine in rats (author's transl)]. Rev Electroencephalogr Neurophysiol Clin (1978) 0.75
Hydergine in senile mental impairment. Gerontology (1982) 0.75
Aspects of sleep-wakefulness architecture by computer analysis in cats. Neuropsychobiology (1988) 0.75
alpha-Adrenoceptive influences on hippocampal theta rhythm in the rat. Behav Neural Biol (1981) 0.75
Influence of zolpidem, a novel hypnotic, on the intermediate-stage and paradoxical sleep in the rat. Pharmacol Biochem Behav (1994) 0.75
The neuroleptics. 3. Pharmacology. Introduction. Mod Probl Pharmacopsychiatry (1970) 0.75
Effects of dihydrogenated ergot alkaloids on the sleep-wakefulness cycle and on brain biogenic amines in the rat. Arzneimittelforschung (1976) 0.75
[A specific domain (the omega 1 site) of the GABA(A) receptor may be implicated in the hypnotic effects of zolpidem]. Encephale (1990) 0.75